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High expression FUT1 and B3GALT5 
is an independent predictor of 
postoperative recurrence and 
survival in hepatocellular carcinoma
Huan-Hsien Kuo1,2, Ruey-Jen Lin1, Jung-Tung Hung1, Chung-Bao Hsieh3, Tsai-Hsien Hung1, 
Fei-Yun Lo1, Ming-Yi Ho1, Chau-Ting Yeh4, Yen-Lin Huang5, John Yu1 & Alice L. Yu1,6
Cancer may arise from dedifferentiation of mature cells or maturation-arrested stem cells. Previously 
we reported that definitive endoderm from which liver was derived, expressed Globo H, SSEA-3 
and SSEA-4. In this study, we examined the expression of their biosynthetic enzymes, FUT1, FUT2, 
B3GALT5 and ST3GAL2, in 135 hepatocellular carcinoma (HCC) tissues by qRT-PCR. High expression 
of either FUT1 or B3GALT5 was significantly associated with advanced stages and poor outcome. 
Kaplan Meier survival analysis showed significantly shorter relapse-free survival (RFS) for those with 
high expression of either FUT1 or B3GALT5 (P = 0.024 and 0.001, respectively) and shorter overall 
survival (OS) for those with high expression of B3GALT5 (P = 0.017). Combination of FUT1 and B3GALT5 
revealed that high expression of both genes had poorer RFS and OS than the others (P < 0.001). 
Moreover, multivariable Cox regression analysis identified the combination of B3GALT5 and FUT1 as an 
independent predictor for RFS (HR: 2.370, 95% CI: 1.505–3.731, P < 0.001) and OS (HR: 2.153, 95% CI: 
1.188–3.902, P = 0.012) in HCC. In addition, the presence of Globo H, SSEA-3 and SSEA-4 in some HCC 
tissues and their absence in normal liver was established by immunohistochemistry staining and mass 
spectrometric analysis.
Liver cancer is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide. The 
majority of primary liver cancers are hepatocellular carcinoma (HCC), which arises from hepatocytes. Hepatitis B 
virus (HBV) infection and aflatoxin B exposure are the two critical pathogenic factors leading to HCC in Eastern 
Asia and sub-Saharan Africa. In contrast, hepatitis C virus (HCV) infection is the major risk factor in Northern 
America, Europe and Japan1–3. Patients with advanced unresectable HCC had dismal outcomes with estimated 
survival rates of 17.5% at 1 year and 7.3% at 2 years4. Although patients with early-stage HCC are amenable to 
treatment by surgical resection, nonsurgical ablation procedures or liver transplantation, the overall survival 
remains poor because of high recurrence rate. Patients who received surgical resection had approximately 70% 
recurrence rate at 5 years5. Thus, identification of biomarkers for predicting relapse of patients with HCC is 
important. So far, vascular invasion, large tumor size and tumor multiplicity have been considered as poor prog-
nostic factors for HCC recurrence after surgical treatments6. With the use of a variety of molecular profiling, 
including oligonucleotide microarray, quantitative reverse-transcription polymerase chain reaction (qRT-PCR), 
mass spectrometry, several biomarker candidates associated with HCC recurrence have been reported7. However, 
none of the candidate biomarkers have been put into clinical practice.
To date, no study has focused on the prognostic values of glycan structures or genes involved in their biosyn-
thesis, even though aberrant glycosylation on glycoproteins or glycolipids is a common feature of cancer cells. 
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These abnormal glycoconjugates contribute to tumorigenic processes such as proliferation and invasion of cancer 
cells, angiogenesis, immune modulation and metastasis8, 9. Many tumor-associated carbohydrate antigens have 
been identified such as polysialic acid, sialy-Lewis antigens, Thomsen-Friedenreich antigen, Thomsen-nouvelle 
antigen (Tn), saialy-Tn, GD2, GD3 and Globo H10. Globo H and stage-specific embryonic antigen-3 (SSEA-3), 
SSEA-4 are globoseries glycosphingolipids (GSLs). SSEA-3, also known as globopentaose (Gb5), is the precursor 
of SSEA-4 and Globo H. It is derived from the transfer of galactose to terminal GalNAc of Gb4 globoside by Beta-
1,3-galactosyltransferase 5 (B3GALT5)11. Addition of a α2-3-linked sialic acid to SSEA-3 by ST3 beta-galactoside 
alpha-2,3-sialyltransferase 2 (ST3GAL2) gives rise to SSEA-412, whereas addition of a α1-2-linked fucose to 
SSEA-3 by fucosyltransferase 1 (FUT1) or FUT2 generates Globo H13. SSEA-3 and SSEA-4 are well-known mark-
ers for human embryonic stem cells and can also be found on human teratocarcinoma cells14, 15. Several recent 
studies reported the expression of SSEA-3 in colorectal cancer16 and breast cancer stem cells13; expression of 
SSEA-4 in renal cell carcinoma17, epithelial ovarian carcinoma18, oral cancer19, glioblastoma multiforme20 and 
basaloid lung cancer21. Globo H is expressed in various epithelial cancers, including breast, colon, ovarian, gastric, 
pancreatic, lung and prostate cancers22, 23. On the other hand, few studies have examined the expression of SSEA-4 
and Globo H in HCC. The presence of SSEA-4 was reported on both Hep-11 and Hep-12 cell lines derived from 
the primary and recurrent HCC tissues, respectively, of a single patient24. Globo H has been detected in the 
majority of 32 HCC tumor specimens by mass spectrometry25. Immunohistochemistry (IHC) analysis of a 16 
HCC associated with HBV revealed expression of Globo H in 12 specimens26. These limited studies have shown 
the presence of SSEA-4 and Globo H in HCC tissues, but the expression of SSEA-3 has yet to be deciphered.
Previously, we have demonstrated that the GSL profiles of human embryonic stem cell changed dramatically 
during differentiation into different lineages. Definitive endoderm, but not neuroectoderm, expressed several 
globosides and lactosides, which was consistent with higher expression levels of FUT1, FUT2 and B3GALT5 
in endodermal lineage than those in neural progenitor cells27. The definitive endoderm is one of the primary 
germ layers that participates in the complex morphogenesis of the gut tube, which is the primitive precursor of 
liver, thymus, lung, pancreas, prostate, GI tract and thyroid28. Since liver cells are derived from endoderm, these 
glycosyltransferases may also play important roles in HCC. The reported detection of Globo H and SSEA-4 in 
HCC suggests the possibility of increased expression of their biosynthetic enzymes FUT1/FUT2 and ST3GAL2, 
respectively, and perhaps, B3GALT5, which is involved in the generation of their precursor, SSEA-3. However, the 
clinical relevance of these globoside biosynthetic enzymes has not been addressed.
In the present study, we examined the mRNA levels of glycosyltransferases, including FUT1, FUT2, B3GALT5 
and ST3GAL2, responsible for the synthesis of Globo H, SSEA-3 and SSEA-4 in 135 HCC specimens by qRT-PCR 
and correlated with clinical-pathological parameters and outcomes of patients. Our data demonstrated for the 
first time that patients with higher expression of the FUT1 and B3GALT5, had shorter relapse-free survival (RFS). 
In addition, we unveiled the expression of SSEA-3 and validated the presence of Globo H, SSEA-3 and SSEA-4 in 
HCC tissues, but not in normal liver, by IHC staining and mass spectrometry analysis.
Results
Expression of FUT1, FUT2, B3GALT5 and ST3GAL2 in HCC tissues. Since cancer cells may arise 
from maturation arrest of immature stem cells or from dedifferentiation of mature cells29, it is likely that Globo H 
and its related biosynthetic enzymes expressed on endodermal cells might also be expressed on liver cancer cells. 
We examined the mRNA expression levels of the FUT1, FUT2, B3GALT5 and ST3GAL2 in tumor specimens of 
135 HCC patients by qRT-PCR. Their clinical characteristics and demographic information were summarized 
in Table 1. The mean age was 57.7 ± 13.1 (range: 19–87) with 82.2% being male. All except 5 of 135 patients had 
chronic hepatitis infection with a majority (70.4%) infected by HBV. Six patients were infected by both HBV and 
HCV and remaining were infected by HCV. Liver cirrhosis was found in 59 cases (43.7%). Tumor sizes ranged 
from 0.8 to 16 cm with a mean size of 5.4 ± 3.9 cm, but less than 5 cm in 65.2%. Furthermore, 74 patients (54.8%) 
had histological grade 1–2 tumors and 66 patients (48.9%) showed evidence of vascular invasion in their tum-
ors. According to the tumor-node-metastasis (TNM) system, 102 patients (75.6%) presented with TNM I + II 
stages. Thirteen patients (9.6%) had tumor metastasis at diagnosis. The median follow-up time was 58.6 months 
(range, 1.4 to 126.24 months). At the time of this report, 47 patients (34.8%) died and the 1 y, 3 y and 5 y overall 
survival rate was 87.2%, 73.7% and 66.4%, respectively. All deaths were related to HCC except three patients who 
died of other diseases. The results of qRT-PCR analyses of the 4 globoside biosynthetic genes in these samples 
were shown as −ΔCT, after subtracting the average of 2 reference genes, GAPDH and GUSB (Fig. 1A). The 
mean expression level was −6.05 ± 1.71 (−10.34 to −1.70) for FUT1, −7.02 ± 3.74 (−16.67 to 0.92) for FUT2, 
−7.48 ± 2.85 (−13.53 to 0.25) for B3GALT5 and −3.28 ± 1.02 (−5.83 to −0.53) for ST3GAL2. The expression 
levels of these 4 genes varied greatly among patients (ANOVA, P < 0.001) and ST3GAL2 expression was signifi-
cantly higher than the other three genes.
Correlation of clinicopathological parameters with the expression levels of FUT1, FUT2, 
B3GALT5 and ST3GAL2. To explore the clinical relevance of the expression levels of these 4 globoside gly-
cosyltransferases, we used the area under curve (AUC) of receiver operating characteristic (ROC) curve to evalu-
ate their predictive values for disease recurrence. Among 135 patients, 4 patients who had persistent disease were 
excluded from relapse analyses, and 83 of 131 patients (63.4%) had disease recurrence. Since the date of relapse 
was not available in 2 patients and one patient in remission died of unrelated cause, the ensuing RFS analyses were 
conducted in 128 patients. As shown in Fig. 1B, the AUCs for FUT1, FUT2, B3GALT5 and ST3GAL2 were 0.591, 
0.512, 0.585 and 0.557, respectively. Based on these findings, we further analyzed the prognostic significance of 
their expression levels in HCC, using Youden index to determine the optimal cutoff values defining high and 
low expression groups. The best cutoff value for predicting recurrence of HCC was −6.433 for FUT1, −7.633 for 
FUT2, −7.724 for B3GALT5 and −3.652 for ST3GAL2. The association of expression of each of the four genes 
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with clinical pathological parameters in 135 patients with HCC was analyzed (Table 2). The expression levels of 
FUT1 were significantly correlated with TNM stage (P = 0.002), tumor number (P = 0.001), vascular invasion 
(P = 0.039), metastasis (P = 0.011) and relapse (P = 0.008). Patients with High expression of FUT1 were at higher 
risk than those with low expression of FUT1 for having TNM III + IV stages (OR: 4.16, 95% CI: 1.58–10.93), 
multiple tumors (OR: 3.90, 95% CI: 1.76–8.63) presence of vascular invasion (OR: 2.08, 95% CI: 1.03–4.20), 
metastasis (OR: 9.52, 95% CI: 1.20–75.59) and relapse (OR: 2.66, 95% CI: 1.28–5.54). The expression of B3GALT5 
showed association with TNM stage (P < 0.001), vascular invasion (P = 0.020), metastasis (P = 0.002), relapse 
Characteristics N (%)
Age (Mean ± SD and range) (years) 57.7 ± 13.1 (19–87)
Gender
  Male 111 (82.2%)
  Female 24 (17.8%)
Drinking history
  Yes 43 (31.9%)
  No 92 (68.1%)
Virus infection
  None 5 (3.7%)
  HBV 95 (70.4%)
  HCV 29 (21.5%)
  HBV + HCV 6 (4.4%)
Tumor size (Mean ± SD and range) (cm) 5.4 ± 3.9 (0.8–16)
  ≦5 88 (65.2%)
  >5 47 (34.8%)
Serum AFP (ng/ml)a
  ≦200 87 (65.4%)
  >200 46 (34.6%)
Edmondson Grade
  1 + 2 74 (54.8%)
  3 + 4 61 (45.2%)
TNM stageb
  I + II 102 (75.6%)
  III + IV 33 (24.4%)
Vascular invasion
  Absent 69 (51.1%)
  Present 66 (48.9%)
Tumor number
  Solitary 84 (62.2%)
  Multiple 50 (37%)
  Diffuse infiltrative 1 (0.7%)
Cirrhosis
  No 76 (56.3%)
  Yes 59 (43.7%)
Metastasis
  No 122 (90.4%)
  Yes 13 (9.6%)
Relapsec
  No 48 (36.6%)
  Yes 83 (63.4%)
  RFS duration median (range) 27.3 (0.7–114.7 months)
Outcomes
  Alive 88 (65.2%)
  Dead 47 (34.8%)
OS duration median (range) 58.6 (1.4–126.6 months)
Table 1. Clinical and pathological characteristics of 135 HCC patients. AFP alpha-fetoprotein, HBV hepatitis 
B virus, HCV hepatitis C virus, TNM tumor-node-metastasis, RFS relapse-free survival, OS overall survival. 
aData not available in 2 patients, bAccording to the American Joint Committee on Cancer (AJCC) TNM staging 
system 7th edition (2010), cTumor persistence in 4 patients.
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(P = 0.002) and survival (P = 0.006). In addition, the odds ratio for TNM III + IV stage, vascular invasion, metas-
tasis, relapse and survival was 6.17 (95% CI: 2.35–16.26), 2.26 (95% CI: 1.13–4.51), 13.24 (95% CI: 1.67–105), 
3.22 (95% CI: 1.53–6.77) and 2.81 (95% CI: 1.33–5.91), respectively. The ST3GAL2 showed a significant associ-
ation with number of tumor nodules (P = 0.003), Edmonson-Steiner grade (P = 0.008) and relapse (P = 0.042). 
When compared to low expression of ST3GAL2, patients with high expression of ST3GAL2 were at higher risk 
for multiple tumors (OR: 3.22, 95% CI: 1.46–7.13), moderately and poorly differentiated tumor (OR: 2.66, 95% 
CI: 1.28–5.53) and relapse (OR: 2.13, 95% CI: 1.02–4.45). On the other hand, the FUT1, B3GALT5, ST3GAL2 
expression levels were not significantly associated with age, virus infection, liver cirrhosis or AFP. As to FUT2, 
there was no significant association with any clinicopathological features (Supplementary Table 1). These findings 
revealed that high expression of FUT1 or B3GALT5 was significantly associated with advanced tumor stage and 
metastatic phenotype of HCC.
High expression levels of FUT1 and B3GALT5 correlate with poor clinical outcome. We further 
investigated whether high expression of FUT1, B3GALT5 and ST3GAL2 was a significant predictor of recurrence 
of HCC. Kaplan-Meier analysis revealed that RFS in patients with high expression of FUT1 (median: 20.0, 95% CI: 
10.86–37.29 months), and B3GALT5 (median: 19.5, 95% CI: 7.8–28.07 months) was significantly shorter than those 
with low expression of FUT1 (median: 56.0, 95% CI: 27.20–77.64 months; P = 0.024) and B3GALT5 (median: 85.1, 
95% CI: 29.80–114.68 months; P = 0.001) (Fig. 2). Patients with high expression of ST3GAL2 tend to have shorter 
RFS, albeit the difference did not reach statistical significance (P = 0.063). Kaplan-Meier analyses of overall sur-
vival (OS) showed that patients with high expression of B3GALT5 had significantly poorer OS than those with low 
expression (P = 0.017), whereas the levels of FUT1 and ST3GAL2 did not significantly correlate with OS (Fig. 3).
To further evaluate the joint effects of FUT1 and B3GALT5, patients were stratified into three groups: high for 
both, low for both and the others, for Kaplan-Meier survival analysis. The RFS and OS were not statistically differ-
ent between the low for both group and others (P = 0.303 and 0.195, respectively) (supplementary Fig. 1s). Thus, 
these two groups were combined into one for comparison with the high for both group. As shown in Fig. 2D, 
patients with high expression of FUT1 and B3GALT5 combined had significantly lower rate of RFS than the 
remaining group (P < 0.001), at 1 year (46.0% vs. 79.2%), 3 years (23.7% vs. 60.2%), and 5 years (21.3% vs. 52.9%). 
In addition, these patients also had significantly shorter OS than the remaining group (P < 0.001) at 1 year (78.4% 
vs. 92.7%), 3 years (56.4% vs. 84.8%) and 5 years (47.8 vs. 78.6%) (Fig. 3D).
High expression of FUT1 and B3GALT5 combined is an independent prognostic factor for HCC 
relapse and overall survival. To evaluate the potential value of the expression levels of FUT1, B3GALT5 
and ST3GAL2 for predicting HCC recurrence and OS, univariate Cox proportional hazard regression analyses 
were conducted. The results indicated that RFS correlated with the patient older than 55-year (HR: 1.960, 95% 
CI: 1.233–3.126, P = 0.005), tumor size greater than 5 cm (HR: 3.113, 95% CI: 1.975–4.906, P < 0.001), presence 
of metastasis (HR: 3.632, 95% CI: 1.891–6.973, P < 0.001), and presence of vascular invasion (HR: 3.317, 95% 
CI: 2.098–5.244, P < 0.001). In addition, RFS duration of HCC patients was significantly associated with high 
expression of FUT1 (HR: 1.698, 95% CI: 1.067–2.701, P = 0.025) and B3GALT5 (HR: 2.082, 95% CI: 1.313–3.302, 
P = 0.002). Similarly, the above-mentioned factors except FUT1 also significantly correlated with OS (Table 3). 
Next, to identify the independent variables associated with poor RFS and OS, we selected those important covar-
iates which showed statistical significance in the univariate analysis for multivariable Cox regression analysis 
in a stepwise manner. As shown in Table 3 in addition to age ≥55, tumor ≥5 cm and vascular invasion, the 
expression levels FUT1 and B3GALT5 combined were independent risk factors for both RFS (HR: 2.370, 95% CI: 
Figure 1. Expression levels of FUT1, FUT2, B3GALT5 and ST3GAL2 in HCC tissues and their ROC analyses in 
relation to disease recurrence. (A) The RNA expression levels of FUT1, FUT2, B3GLAT5 and ST3GAL2 in HCC 
tissues were determined by qRT-PCR. The CT value of each specimen was normalized to the average of control 
and presented as minus delta threshold cycle (−ΔCt). (B) The values of −ΔCt of FUT1, FUT2, B3GLAT5 and 
ST3GAL2 were used to plot the ROC curves to predict the relapse of patients with HCC. AUC: area under curve.
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1.505–3.731, P < 0.001) and OS (HR: 2.153, 95% CI: 1.188–3.902, P = 0.012) in patients with HCC. These findings 
identified the combined expression of FUT1 and B3GALT5 as an important and independent predictor for RFS 
and OS in HCC patients.
Determination of the expression of Globo H, SSEA-3 and SSEA-4 in HCC and normal liver tis-
sues. Only a few studies reported the presence of SSEA-4 and Globo H in HCC tissues25, 26, 30 and the expres-
sion of SSEA-3 has yet to be deciphered. To examine the expression of SSEA-4, SSEA-3 and Globo H on HCC 
tissues, we obtained paraffin-embedded HCC tissue sections and performed IHC staining with monoclonal anti-
bodies against the SSEA-4, SSEA-3 and Glob H, respectively. Positive IHC stainings from 2 representative HCC 
Variable N
FUT1 B3GALT5 ST3GAL2
Low High
P 
valuea OR (95% CI) Low High P valuea OR (95% CI) Low High
P 
valuea OR (95% CI)
Age
  <55 56 23 33
0.948
1.0 25 31
0.493
1.0 23 33
0.608
1.0
  ≧55 79 32 47 1.02 (0.51–2.05) 40 39 0.79 (0.40–1.56) 29 50 1.20 (0.60–2.43)
Gender
  Female 24 9 15
0.722
1.0 7 17
0.040
1.0 6 18
0.133
1.0
  Male 111 46 65 0.84 (0.34–2.10) 58 53 0.38 (0.15–0.98) 46 65 0.47 (0.17–1.28)
Virus infection
  None 5 2 3
0.986
1.0 1 4
0.311
1.0 1 4
0.323
1.0
  HBV 95 39 56 0.96 (0.15–6.00) 50 45 0.23 (0.02–2.09) 41 54 0.33 (0.03–3.06)
  HCV 29 12 17 0.94 (0.14–6.54) 11 18 0.41 (0.04–4.15) 9 20 0.56 (0.05–5.70)
  HBV + HCV 6 2 4 1.33 (0.11–15.70) 3 3 0.25 (0.17–3.77) 1 5 1.25 (0.06–26.87)
Liver cirrhosis
  No 76 35 41
0.154
1.0 38 38
0.625
1.0 32 44
0.331
1.0
  Yes 59 20 39 1.66 (0.82–3.36) 27 32 1.19 (0.60–2.34) 20 39 1.42 (0.70–2.87)
TNM stage
  I + II 102 49 53
0.002
1.0 59 43
<0.001
1.0 42 60
0.265
1.0
  III + IV 33 6 27 4.16 (1.58–10.93) 6 27 6.17 (2.35–16.26) 10 23 1.61 (0.70–3.73)
Tumor size (cm)
  ≦5 88 39 49
0.247
1.0 47 41
0.094
1.0 35 53
0.682
1.0
  >5 47 16 31 1.54 (0.73–3.21) 18 29 1.85 (0.90–3.80) 17 30 1.17 (0.56–2.42)
AFP (ng/mL)b
  ≧200 87 34 53
0.803
1.0 43 44
0.679
1.0 35 52
0.539
1.0
  >200 46 19 27 0.91 (0.44–1.88) 21 25 1.16 (0.57–2.38) 16 30 1.26 (0.60–2.65)
Tumor numberc
  Solitary 84 44 40
0.001
1.0 43 41
0.421
1.0 40 44
0.003
1.0
  Multiple 50 11 39 3.90 (1.76–8.63) 22 28 1.34 (0.66–2.70) 11 39 3.22 (1.46–7.13)
Grade
  1–2 74 32 42
0.515
1.0 33 41
0.363
1.0 36 38
0.008
1.0
  3–4 61 23 38 1.259 (0.63–2.51) 32 29 0.73 (0.37–1.44) 16 45 2.66 (1.28–5.53)
Vascular invasion
  Absent 69 34 35
0.039
1.0 40 29
0.020
1.0 26 43
0.838
1.0
  Present 66 21 45 2.08 (1.03–4.20) 25 41 2.26 (1.14–4.51) 26 40 0.93 (0.47–1.86)
Metastasis
  No 122 54 68
0.011
1.0 64 58
0.002
1.0 50 72
0.071
1.0
  Yes 13 1 12 9.52 (1.20–75.59) 1 12 13.24 (1.67–105). 2 11 3.82 (0.81–17.98)
Relapsed
  No 48 27 21
0.008
1.0 31 17
0.002
1.0 23 25
0.042
1.0
  Yes 83 27 56 2.66 (1.28–5.54) 30 53 3.22 (1.53–6.77) 25 58 2.13 (1.02–4.45)
Survival
  Alive 88 41 47
0.058
1.0 50 38
0.006
1.0 33 55
0.74
1.0
  Death 47 14 33 2.05 (0.96–4.36) 15 32 2.81 (1.33–5.91) 19 28 0.88 (0.43–1.83)
Table 2. Association of FUT1, B3GALT5, and ST3GAL2 expression with clinical-pathological parameters 
in 135 patients with HCC. HBV hepatitis B virus, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP 
alpha-fetoprotein, OR Odds Ratio. aPearson Chi-square test. bData not available in 2 patients. cOne patient with 
diffuse infiltrating tumor was excluded, d4 patients with persistent tumor were excluded. Statistically significant 
values are displayed in boldface.
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specimens for each glycan antigen were shown in Fig. 4A. In general, IHC staining patterns of all three globo-
sides were heterogeneous. In most cases, Globo H positive cells were observed in clusters within the tumor but 
occasionally dispersed Globo H positive cells were also noted. The majority of Globo H positive cells displayed 
membranous and/or uneven cytoplasmic staining, while nuclear staining was rarely seen. SSEA-4 staining usually 
appeared in patches of uniformly staining cells with predominant membranous pattern and in some cases with 
nuclear staining. SSEA-3 positive cells were usually dispersed throughout the tumor, with discrete and granular 
staining of the whole cell in some cases and nuclear staining only in others. However, in light of the reported 
cross-reactivities of anti-glycan antibodies observed by glycan array assay31, we confirmed the presence of these 
glycans by mass spectrometric analysis of GSLs extracted from the tumor tissues that stained positively for Globo 
H, SSEA-4 or SSEA-3 on IHC. Purified GSLs were analyzed by MALDI-TOF mass spectrometry. On the basis 
of the m/z values of major molecular ion signals and the usual ranges of common permutations of sphingosine 
and fatty acyl along with the characteristics of GSLs, the signals of FucHex4HexNAc1Cer (m/z = 1,838/1,950) and 
Hex4HexNAc1Cer (m/z = 1,664/1,774) that represented Globo H and SSEA-3 were found in the neutral fraction. 
In the acidic fraction, the signals with Neu5Ac1Hex4HexNAc1Cer (m/z = 2,025/2,135) which corresponded to 
SSEA-4 were detected (Fig. 4B). The molecular ions at m/z 2,025 were further confirmed by additional MS/MS 
analysis. The major afforded fragment ions were annotated, including the ion at m/z 548 which revealed the 
ceramide moiety, B ions at m/z 376 and 847 corresponding to terminal Neu5Ac and Neu5ACHexHexNAc, Y ion 
at 1,650 deriving from loss of Neu5Ac and C ion at m/z 1,478 produced through glycosidic cleavage at glucose 
extending from ceramide. Ions at m/s 449 and 472 corresponding to internal Hex2 and HexHexNAc units were 
also detected. These MS/MS data identified the molecular ion signals at m/z 2,025 as SSEA-4 (Fig. 4C). Recently, 
Zhu et al. demonstrated that Globo H was detected in HCC tissues by mass spectrometry. We also identified 
Globo H in HCC by using leech ceramide glycanase to release glycans from GSLs, and then analyzed by LC MS/
MS (Data not shown).
Next, we performed IHC to examine the expression of SSEA-3, -4 and Globo H in normal liver tissues 
obtained from two trauma patients. None of these three globosides were detected by IHC staining of normal 
liver, although weak non-specific granular signals were observed for SSEA-3 staining (Fig. 5A). This was further 
confirmed by MALDI-TOF MS analyses of the GSLs extracted from the same tissues, showing that the majority of 
GSLs in the neutral fraction were lactosylceramide (LacCer), globotriaosylceramide (Gb3) and globoside (Gb4)/ 
neolactotetraosylceramide (nLc4) (Fig. 5B). No signal for Globo H or SSEA-3 was detected. In the acidic fraction, 
Figure 2. Kaplan-Meier plots of RFS for patients with HCC in relation to FUT1, B3GALT5, and ST3GAL2 
expression level. Patients with high level of FUT1 (A), B3GALT5 (B), ST3GAL2 (C), and FU1 + B3GALT5 
combined (D) had poorer RFS. Seven of 135 patients were excluded from relapse analyses: 4 patients who had 
persistent disease, one patient who died of unrelated cause while in remission, and 2 patients for whom the date 
of relapse was not available.
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the most abundant GSLs was GM3, and no SSEA-4 was detected. Taken together, Globo H, SSEA-3 and SSEA-4 
are not expressed in normal liver tissues.
Discussion
In this study, we provide the first evidence that expression level of FUT1, B3GALT5 and ST3GAL2, the enzymes cata-
lyzing the synthesis of three globosides, Globo H, SSEA-3 and SSEA-4, was associated with adverse clinical features. 
Greater expression of either FUT1 or B3GALT5 in HCC tissue was associated with poor prognosis. More importantly, 
high expression of these two genes combined emerged as an independent predictor for RFS and OS in HCC.
Overexpression of FUT1 had been reported in colon cancer32 and shown to confer resistance to serum 
starvation-induced cell death33. Since serum starvation elicits autophagy, the protection conferred by FUT1 may 
be explained by our recent findings that FUT1 impedes perinuclear localization of lysosomes via fucosylation of 
LAMP1 and LAMP2, thereby preventing autophagic death34. In addition, our findings in this study are consistent 
with several reports by others. Zhang et al. found that knockdown of FUT1 by siRNA in epidermoid carcinoma 
cell line A431 inhibited tumor growth in mice35. Goupille et al. observed increasing tumorigenicity in vivo of rat 
colon carcinoma cells transfected with FUT136. Furthermore, Amin et al. demonstrated that FUT1 played an 
important role in angiogenesis in vitro and in vivo with the use of FUT1 null endothelial cells and FUT1 knockout 
mice37. Also, data mining of breast cancer by Milde-Langosch et al. showed that high expression of FUT1 was a 
poor prognostic factor for breast cancer and associated with distant metastasis38. These studies were in line with 
our findings that high expression of FUT1 in HCC was associated with vascular invasion and multiple tumor 
nodules. On the other hand, Mathieu et al. reported that introducing FUT1 into HepG2 cells inhibited angiogen-
esis and tumor growth39. However, the HepG2 cell is a hepatoblastoma40, which is an embryonal malignancy of 
hepatocellular origin and has different clinical features distinctive from HCC. Such differences may account for 
the differential roles of FUT1 in hepatoblastoma HepG2 cell and HCC.
Besides FUT1, we also showed high expression of B3GALT5 in HCC tissues to be associated with advanced 
TNM stage, metastasis, vascular invasion and tumor recurrence. Among the 6 members of beta 1–3 galacto-
syltransferase family, B3GALT5 has broadest range of acceptors. In addition to transferring a galactose to the 
terminal GalNAc of GB4 to generate SSEA-3, B3GALT5 is also responsible for the synthesis of type 1 chain 
(Galβ1-3GlcNAc), which is the precursor of Lewis A and sialyl Lewis A (SLea), the latter is also known as CA19-9 
antigen. Along this line, the expression of B3GALT5 was shown to be correlated with CA19-9 in pancreatic cell 
lines and cancer tissues41, 42. SLea is a ligand for selectins and mediates adhesion of cancer cell to endothelial 
cells and promotes tumor progression43. Similarly Chung et al.44 reported that overexpression of HBV X protein 
in Chang cell enhanced SLea expression and mediated cell adhesion to endothelial cell and metastasis through 
Figure 3. Kaplan-Meier plots of overall survival for patients with HCC in relation to the expression levels of 
FUT1 (A), B3GALT5 (B), ST3GAL2 (C) and FUT1 + B3GALT5 combined (D).
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induction of B3GALT5. Thus, it is possible that high expression of B3GALT5 might promote tumor metastasis 
through SLea and other glycans in HCC tissue.
Moreover, we found that higher expression of ST3GALT2 was associated with the number of HCC tumor nod-
ules and high histological grades. The molecular mechanisms by which ST3GAL2 directly or indirectly contributes 
to tumor progression are not clear. SSEA-4 is a well-known product generated by ST3GAL2. Although the biological 
function of SSEA-4 is still unclear, it has been identified as a marker for human embryonic stem cells as well as cancer 
stem cells in breast cancer45. In addition, Yang et al. reported that knockdown of ST3GAL2 significantly reduced 
the phosphorylation of ERK1/2 and EGFR in the osteoblasts46. Since EGFR pathway is known to contribute to the 
inflammation in the liver and hepatocarcinogenesis47, ST3GAL2 might promote tumorigenesis through EGFR path-
way. Saito et al. reported higher expression of ST3GAL2 in renal cell carcinoma tissues than in non-tumor kidney, 
suggesting that ST3GAL2 might be involved in the malignant processes12. In addition, Aloia et al. identified a sub-
population of breast cancer cells carrying high levels of SSEA-4 to be resistant to chemotherapy drugs and showed 
ST3GAL2 to be a marker of poor outcome in breast cancer and ovarian cancer patients undergoing chemotherapy48. 
These reports are in line with our finding that high expression of ST3GAL2 is associated with HCC progression.
In this study, we provided the first evidence for SSEA-3 expression in HCC by immunohistochemistry and 
mass spectrometry. We also confirmed the presence of both SSEA-4 and Globo H in HCC tumor cells by IHC 
staining and mass spectrometric analysis of GSLs from HCC tumor tissues. Furthermore, none of these three 
globosides were found in normal liver tissues by either IHC or mass spectrometry. There are only a few stud-
ies addressing the biological functions of Globo H, SSEA3 and SSEA-4. Sorting of SSEA3+ cells from breast 
cancer stem cell subpopulation of MCF-7 and MDA-MB-231 cell lines further enhanced their tumor initiating 
capacity49. In addition, clustering of SSEA-4 by the monoclonal antibody promotes invasion ability of the breast 
cancer cell line through activation of cSrc and FAK50. Apart from these studies, the functions of SSEA-3 and 
SSEA-4 remain an enigma. Previously, our studies demonstrated that Globo H could promote angiogenesis 
through its interaction with Translin-Associated Factor X (TRAX), with consequent release and activation of 
phospholipase C β1 from TRAX to trigger Ca2+ mobilization51. In addition, Globo H acted as an immune check-
point to facilitate the escape of tumor cells from immune surveillance by suppressing the activation of B-cell 
and T-cell52. These findings provided strong rationales for Globo H-targeted immunotherapy of cancer. Indeed, 
clinical trials of Globo H vaccine have generated promising results53.
In the present study, we found that high expression of either FUT1 or B3GALT5 was a significant risk factor 
for HCC relapse and high expression of B3GALT5 correlated with OS, but neither alone was an independent 
predictor for HCC recurrence or OS. Notably, multivariable analyses showed that a combination of high expres-
sion of FUT1 and B3TALT5 is an independent risk factor for recurrence and OS, in addition to vascular invasion 
and tumor size greater than 5 cm. The latter two were consistent with reports in many studies6. We are currently 
variables
RFS OS
Univariate analysis Multivariable analysis Univariate analysis Multivariable analysis
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age: ≥55 vs. <55 1.960 1.223–3.126 0.005 1.875 1.173–2.999 0.009 2.177 1.150–4.120 0.017 2.096 1.095–4.011 0.026
Gender: male vs. female 0.709 0.410–1.228 0.220 0.592 0.308–1.140 0.119
Hepatitis virus infection: 
yes vs. no 0.801 0.293–2.190 0.665 1.712 0.239–12.293 0.595
Cirrhosis: present vs. 
absent 1.237 0.797–1.920 0.344 0.815 0.454–1.465 0.496
Tumor size (cm): ≥5 
vs. <5 3.113 1.975–4.906 <0.001 2.042 1.248–3.344 0.005 4.283 2.384–7.694 <0.001 2.728 1.452–5.126 0.002
AFP (ng/ml): ≥200 vs. 
<200 1.128 0.707–1.800 0.612 1.291 0.711–2.344 0.403
Tumor number: mutiple 
vs. solitary 1.328 0.845–2.087 0.219 1.623 0.910–2.897 0.103
Grade: III + IV vs I + II 0.888 0.571–1.382 0.600 0.651 0.357–1.188 0.164
Vascular invasion: absent 
vs. present 3.317 2.098–5.244 <0.001 2.173 1.323–3.570 0.002 5.305 2.638–10.665 <0.001 2.792 1.305–5.975 0.008
Metastasis: yes vs. no 3.632 1.891–6.973 <0.001 NS 4.207 2.084–8.493 <0.001 NS
FUT1: high vs. low 1.698 1.067–2.701 0.025 NS 1.731 0.929–3.224 0.086
B3GALT5: high vs. low 2.082 1.313–3.302 0.002 NS 2.081 1.130–3.831 0.019 NS
ST3GAL2: high vs low 1.568 0.971–2.533 0.066 0.987 0.552–1.763 0.965
FUT1 + B3GALT5 
combined: high for both 
vs others
2.927 1.877–4.564 <0.001 2.370 1.505–3.731 <0.001 2.908 1.627–5.196 <0.001 2.153 1.188–3.902 0.012
Table 3. Univariate and multivariable Cox proportional regression analysis of factors associated with HCC 
recurrence and survival. RFS relapse-free survival, OS overall survival, HR hazard ratio, CI confidence interval, 
NS not significant; Multivariable modeling using stepwise variable selection. Statistically significant values are 
displayed in boldface.
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investigating the expression of Globo H, SSEA-3 and SSEA-4 in more HCC samples, in relation to these three 
glycosyltransferases and their clinical relevance.
The risk factors and incidence of HCC vary greatly according to geographic regions and ethnicities. The 
patients in our study were Taiwanese with HCC which were mostly (96.3%) associated with viral hepatitis. Thus, 
it remains to be determined if our finding of high expression of combined FUT1 and B3GALT5 as an independent 
risk factor for postoperative recurrence and OS in patients with resectable HCC will apply to HCC patients from 
different ethnicities or different etiologies, such as alcoholic and nonalcoholic steatohepatitis.
Figure 4. Expression of Globo H, SSEA-4 and SSEA-3 and in HCC. (A) Expression of Globo H, SSEA-4 and 
SSEA-3 in formalin-fixed, paraffin-embedded HCC tissue sections was determined by IHC staining with mAbs 
VK9, MC-813-70 and MC-631, respectively. Two representative positive stainings for each of the 3 globosides 
and their isotype controls were shown. Scale bars indicate 60 μm (original magnification 40X) (B) MALDI-
TOF MS spectra of permethylated GSLs derived from an HCC tumor tissue which showed positive IHC 
stainings for Globo H, SSEA-4, and SSEA-3. Signals of Fuc1Hex4HexNAc1Cer (Globo H, m/z = 1,838/2,050) and 
Hex4HexNAc1Cer (SSEA-3, m/z = 1,664/1,774) were found in the neutral fraction. Neu5AC1Hex4HexNAcCer 
(SSEA-4, m/s = 2,025/2,135) was detected in the acidic fraction. These GSLs carried both C16:0 and C24:0/
C24:1 ceramides (at 112/110 mass units higher than those with C16:0) (C) MALDI CID MS/MS spectra of the 
precursor at m/z 2,025 (SSEA-4). Assignments of fragment ions were shown on the illustrations. Only the O 
atoms at preferred cleavage sites were drawn out to distinguish between B and C ions.
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In conclusion, our finding of combined high expression of FUT1 and B3TALT5 as an independent risk factor 
for postoperative recurrence and OS of HCC represents a simple and valuable addition to the existing clinico-
pathological parameters for the prognostication of HCC. Surgical resection is the main stay of HCC treatment. 
However, high incidence rate of recurrence and lack of simple and reliable biomarkers for predicting postoper-
ative recurrence is still a challenge. If confirmed in large cohort study, our findings provide an important arma-
mentarium to fill the void. Furthermore, we have shown here that Globo H, SSEA-3 and SSEA-4 were expressed 
in HCC tissues but not in normal liver tissue. Thus, these GSLs and glycosyltransferase could be potential thera-
peutic targets for HCC.
Materials and Methods
Clinical specimens. Complementary DNA (cDNA) or total RNA extracted from surgically resected tumors, 
along with relevant clinical and pathological data from 135 patients with American Joint committee on Cancer 
HCC stage I to IV were obtained from Linkou Chang Gung Memorial Hospital and Taiwan Liver Cancer Network. 
Snap-Frozen HCC tissues used for GSL extraction were obtained from Tissue Bank of Tri-Service General Hospital, 
Figure 5. Lack of Globo H, SSEA-4 and SSEA-3 expression in normal liver tissue as determined by IHC and 
MALDI-MS analyses of permethylated GSLs. (A) Formalin-fixed, paraffin-embedded normal liver tissue 
sections from two cases were stained with mAbs VK9, MC-813-70 and MC-631 for the detection of Globo 
H, SSEA-4, and SSEA-3, respectively. Scale bars indicate 60 μm (original magnification 40X) (B) Total GSLs 
extracted from case 1 were separated into neutral and acidic fractions, permethylated and analyzed by MALDI-
TOF mass spectrometry. The major GSLs in the neutral fraction were LacCer, Gb3, Gb4/nLc4, and GM3, GD3 
and GM1a/b were found in the acidic fraction. GSLs with the same glycan moiety but with different fatty acyl 
contents were bracketed.
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Taipei, Taiwan. Normal liver tissues and sections were obtained from trauma patients from the Tissue Bank of 
Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. Informed consent was obtained from all subjects before 
their tissues were deposited. All methods were carried out in accordance with relevant guidelines and regulations 
and approved by Institutional Review Board of Chang Gung Medical Foundation, Institutional Review Board of Tri-
Service General Hospital, and Biobank Ethics Committee of National Health Research Institutes.
Immunohistochemistry. The primary antibodies used included the following: mAb VK9 for Globo H, 
(hybridoma provided by Dr. Govindaswami Ragupathi, Memorial Sloan-Kettering Cancer Center, New York, 
NY), anti-SSEA-4 (MC-813-70, R&D Systems, Minneapolis, MN) and anti-SSEA-3 (MC-631, R&D Systems, 
Minneapolis, MN). IHC analysis was performed on formalin-fixed, paraffin-embedded tissue. Sections (3 μm) 
on coated slides were deparaffinized and rehydrated, then subjected to antigen retrieval by autoclave at 121 °C 
for 5 minutes in antigen Retrieval AR-10 solution (BioGenex, Fremont, CA) for SSEA-3 and Globo H or in 
Target Retrieval Solution (Dako, Glostrup, Denmark) for SSEA-4. Sections were treated with H2O2 and then 
incubated with primary antibodies at 4 °C overnight, followed by staining with Super Sensitive Polymer-HRP 
Detection System (BioGenex, Fremont, CA) and developed by DAB substrate (BioGenex, Fremont, CA). Slides 
were counter-stained with Harris’ hematoxylin and mounted. Sections were examined by pathologists and digital 
images were captured by Aperio Scope AT Turbo Slide Scanner (Leica Biosystems) at 40X magnification.
Quantitative reverse-transcription real-time polymerase chain reaction. Total RNA (1 μg) was con-
verted to cDNA using high capacity cDNA reverse transcription kit (Applied Biosystems, CA, USA) according 
to the manufacturer’s instructions. The expression levels of FUT1, FUT2, B3GALT5 and ST3GAL2 were deter-
mined by using TaqMan Gene Expression Master Mix on an Applied Biosystems 7500 fast real-time PCR system. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and glucuronidase beta (GUSB) were used as endogenous 
controls. The TaqMan probes for the detection of FUT1 (Hs00355741_m1), FUT2 (Hs00382834_m1), B3GALT5 
(Hs00707757_s1), ST3GAL2 (Hs00911835_m1), GAPDH (Hs99999905_m1) and GUSB (Hs99999908_m1) were 
purchased from Applied Biosystems. Ten nanograms of cDNA sample were used for the qRT-PCR reaction follow-
ing the manufacturer’s instructions. The fluorescent signals were analyzed by 7500 software v2.06.
Matrix-assisted laser desorption ionization-time of flight (MALD-TOF) analysis of permeth-
ylated GSLs. GSLs were extracted from HCC tissue as described54. Briefly, frozen tissue (approximately 
25 mg) was homogenized and extracted with methanol and chloroform and bath-sonicated for 30 min. After 
centrifugation, the supernatant was collected, and the pellet was extracted three times with the same solvent. The 
supernatants containing neutral and acidic GSLs were pooled. Neutral and acidic GSLs were further separated 
by anion-exchange chromatography. The purified GSLs were subjected to permethylation according to NaOH/
DMSO method55. MS analyses were carried out on an SCIEX 5800 MALDI-TOF/TOF mass spectrometer using 
2,5-dihydroxybenzoic acid as matrix. MS spectra were acquired in positive-ion mode and accumulated in 4000 
laser shots with random sampling to increase the spectral reproducibility.
Statistical Analysis. Data are presented as mean ± SD, count and percentages. The prognostic performance 
of genes was calculated by the receiver operating characteristic curve and the area under the ROC curve. The 
Youden index (sensitivity + specificity −1) was used to determine the optimal cut-off value for high versus low 
gene expression level. Survival curves were plotted by Kaplan–Meier method, with the log-rank test applied for 
comparison. The Cox proportional-hazards regression model was employed to evaluate the independent prog-
nostic factors. All tests were two-sided and P-values < 0.05 were considered statistically significant. The statistical 
analyses were performed with Prism 5.0 (GraphPad Software, La Jolla, CA, USA) and MedCalc 14.8 (MedCalc 
Software, Ostend, Belgium) software.
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